



PATENT

Attorney Docket No. 06267.0126-00000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
)
Tomi JÄRVINEN et al.) Group Art Unit: 1626
)
Application No.: 10/537,622) Examiner: Laura L. STOCKTON
)
Int'l Filing Date: December 5, 2003)
§ 371 Date March 29, 2006)
) Confirmation No.: 8385
For: IMIDAZOLE DERIVATIVES)
HAVING AFFINITY FOR ALPHA 2)
RECEPTORS ACTIVITY (as)
amended)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(c)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(c), Applicants bring to the attention of the Examiner the documents on the attached listing. This Information Disclosure Statement is being filed after the events recited in Section 1.97(b) but, to the undersigned's knowledge, before the mailing date of either a Final action, Quayle action, or a Notice of Allowance. Under the provisions of 37 C.F.R. § 1.97(c), this Information Disclosure Statement is accompanied by a fee of \$180.00 as specified by Section 1.17(p).

Copies of the non-patent literature documents are attached.

07/02/2007 JADD01 00000017 10537622

01 FC:1806

180.00 00

Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claims in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserves the right to present to the office the relevant facts and law regarding the appropriate status of such documents.


Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: June 29, 2007

By: 
Jill K. MacAlpine
Reg. No. 60,475

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of

1

Application Number

10/537,622

Filing Date

March 29, 2006

First Named Inventor

Tomi JÄRVINEN et al.

Art Unit

1626

Examiner Name

Laura L. STOCKTON

Attorney Docket Number

06267.0126-00000

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS

Examiner Initials	Cite No. ¹	Document Number	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				

NONPATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation ⁶
	1	Esler, M. et al. "Increase sympathetic nervous system activity and its therapeutic reduction in arterial hypertension, portal hypertension and heart failure," <i>J. Autonomic Nervous System</i> (1998) 72:210-219.	
	2	Lal, H. et al. "Psychopharmacology of Clonidine: An Introduction," <i>Psychopharmacology of Clonidine</i> (1981) Alan R. Liss, Inc., New York, NY: 1-3.	
	3	Gold, M. S. et al. "Neuroanatomical Sites of Action of Clonidine in Opiate Withdrawal: The Locus Coeruleus Connection," <i>Psychopharmacology of Clonidine</i> (1981) Alan R. Liss, Inc., New York, NY: 285-298.	
	4	Gold, M. S. et al. "Clinical Utility of Clonidine in Opiate Withdrawal: A Study of 100 Patients," <i>Psychopharmacology of Clonidine</i> (1981) Alan R. Liss, Inc., New York, NY: 299-306.	

Examiner
SignatureDate
Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.